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A B S T R A C T
Here we describe carbapenem resistance determinants in two Klebsiella pneumoniae isolates recovered
from two hospitalised patients in the same intensive care unit of a cancer hospital in Cairo, Egypt. PCR
and sequencing were used to detect and characterise b-lactamase genes. Clonal relationships between
the isolates were analysed by pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus sequence typing
(MLST). The ﬁrst K. pneumoniae isolate carried the blaNDM-1 gene and the second isolate carried the
blaOXA-163 gene. Both isolates co-expressed the extended-spectrum b-lactamase CTX-M-15. The two
isolates belonged to different sequence types (STs), ST11 and ST16, respectively. No history of travel was
established for the two patients. The ﬁrst identiﬁcation of NDM-1-producing K. pneumoniae in Egypt
adds further evidence to the spread of NDM-1-producing Gram-negative micro-organisms in North
Africa. The additional detection of blaOXA-163 in a K. pneumoniae isolate conﬁrms its endemic presence in a
critical healthcare setting of this geographic area.
 2013 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All
rights reserved.
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Infections caused by multidrug-resistant strains of Klebsiella
pneumoniae are spreading widely all over the world [1]. These
infections are associated with high morbidity and mortality,
mainly in immunocompromised individuals such as cancer
patients [2]. They have become highly prevalent in some
geographic areas, including Mediterranean countries and the
Middle East [1].
Carbapenems are ﬁrst-line drugs for severe infections caused by
extended-spectrum b-lactamase (ESBL)-producing K. pneumoniae
strains. However, the worldwide spread of carbapenemase-
producing clones is severely undermining the efﬁcacy of these
antimicrobials [1]. In Egypt, isolation of carbapenem-resistant K.
pneumoniae has been reported in the last years [3].
Here we report two autochthonous cases of infection caused by
two carbapenem-resistant K. pneumoniae isolates, producing
NDM-1 and OXA-163, respectively, in two cancer patients in
Cairo, Egypt, in 2012. The phenotypic and molecular characteristics
of the two isolates are described.* Corresponding author. Tel.: +39 091 655 3623; fax: +39 091 655 3641.
E-mail address: caterina.mammina@unipa.it (C. Mammina).
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2.1. Patients and bacterial isolates
Case 1 was a 56-year-old male hospitalised on 6 July 2012 with
a diagnosis of adenocarcinoma of the gastro-oesophageal tract. On
4 October 2012, he was admitted to the intensive care unit (ICU)
owing to severe sepsis. A gastric ﬂuid sample was taken that
yielded imipenem-resistant K. pneumoniae (isolate 39). The patient
started on therapy with levoﬂoxacin and teicoplanin. Thereafter,
he was submitted to oesophagectomy and gastric pull-up on 16
October 2012.
Case 2 was a 45-year-old male. He had a diagnosis of acute
myeloid leukaemia on 3 November 2012. Because of cardiac and
renal impairment with fever, he was admitted to the ICU on 26
November 2012 and was started on meropenem, vancomycin,
amikacin and acyclovir. A blood culture was positive for
carbapenem-resistant K. pneumoniae (isolate 181). The previous
antibiotic treatment was interrupted and a combination of
imipenem and levoﬂoxacin was administered.
In both cases the treatment was reported as effective. Both
patients were hospitalised at the National Cancer Institute (NCI)
(Cairo, Egypt) and had never travelled outside of Egypt.
Identiﬁcation and antibiotic susceptibility testing of the K.
pneumoniae isolates was carried out at the microbiology laboratoryction and Cancer. Published by Elsevier Ltd. All rights reserved.
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nostics).
2.2. Antimicrobial susceptibility testing
The two carbapenem-resistant K. pneumoniae strains were sent
to the molecular epidemiology laboratory of the Department of
Sciences for Health Promotion and Mother–Child Care ‘G.
D’Alessandro’, University of Palermo (Palermo, Italy) for conﬁrma-
tion and typing. Susceptibility testing to third-generation cepha-
losporins, carbapenems, gentamicin, ﬂuoroquinolones, colistin and
tigecycline was performed with Etest strips (bioMe´rieux, Marnes-
la-Coquette, France). Results were interpreted according to
European Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines [4].
2.3. Molecular characterisation
PCR screening for carbapenemase-encoding genes of classes A
(blaKPC, blaGES), B (blaVIM, blaIMP, blaNDM) and D (blaOXA-48) and for
ESBL-encoding genes blaTEM, blaOXA, blaSHV and blaCTX-M was
performed as described previously [5,6]. PCR products were
puriﬁed and sequenced using a BigDye1 Terminator v.1.1 Cycle
Sequencing Kit (Applied Biosystems, Warrington, UK) and an ABI
Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
The nucleotide and deduced protein sequences were analysed with
the software available from the National Center for Biotechnology
Information (NCBI) website (http://www.ncbi.nlm.nih.gov).
Multiplex PCR for detecting 16S rRNA methylase genes was
carried out according to Berc¸ot et al. [7]. Plasmid-mediated
quinolone resistance genes qnrA, qnrB, qnrC, qnrD, qnrS, qepA and
aac(60)-Ib-cr were also investigated by PCR as described previously
[8]. The identity of resistance genes was conﬁrmed by DNA
sequence analysis. Outer membrane protein (OMP) gene ampliﬁ-
cation was conducted using ompK35-F and -R and ompK36-F and -
R, and PCR products were sequenced using OMP primers according
to Kaczmarek et al. [9]. Sequences were analysed by comparison
with reported nucleotide sequences in GenBank. Expression levels
of the ompK35 and ompK36 genes were not investigated.
To assess clonality, the two isolates were submitted to pulsed-
ﬁeld gel electrophoresis (PFGE) following XbaI DNA digestion. In
addition, multilocus sequence typing (MLST) was performed on
both isolates according with the protocol described on the K.
pneumoniae MLST website (http://www.pasteur.fr/recherche/
genopole/PF8/mlst/Kpneumoniae.html). MLST results were com-
pared with the international K. pneumoniae MLST database at the
Pasteur Institute (Paris, France).
3. Results
The phenotypic and genetic antimicrobial drug resistance
characteristics of the two K. pneumoniae isolates are summarised
in Table 1. The isolates exhibited resistance to extended-Table 1
Phenotypic and genetic characteristics of the two Klebsiella pneumoniae isolated in Cai
K. pneumoniae
strain
ST bla genes PMQR determinants RNA
methylases
MIC
CAZ
39 11 TEM-1, SHV-11,
CTX-M-15, NDM-1
qnrB1 + aac(60)-Ib-cr – >25
181 16 TEM-1, SHV-1,
CTX-M-15, OXA-163
qnrB1 + aac(60)-Ib-cr – >25
ST, sequence type; PMQR, plasmid-mediated quinolone resistance; MIC, minimum inh
cefepime; LEV, levoﬂoxacin; CIP, ciproﬂoxacin; GEN, gentamicin; MEM, meropenem; IP
a MICs assessed by Etest.spectrum cephalosporins, aztreonam and carbapenems. In
addition, both isolates were resistant to ciproﬂoxacin and were
susceptible to colistin and tigecycline. Isolate 39 was also
resistant to gentamicin.
For both isolates, positive PCR results were obtained for the
blaTEM, blaSHV and blaCTX-M genes (Table 1). The ESBL CTX-M-15
was detected in both isolates. Moreover, PCR results showed that
isolate 39 was positive for blaNDM and isolate 181 was positive for
blaOXA-48-like. Sequencing identiﬁed the blaNDM as NDM-1 and the
blaOXA-48-like as OXA-163 (Table 1). Both isolates tested positive for
aac(60)-Ib-cr and qnrB1. The ompK35 and ompK36 genes of isolate
181 were ampliﬁed, sequenced and aligned with those of OMP
gene sequences of K. pneumoniae MGH78578. The ompK35 gene of
the isolate showed an indistinguishable sequence from that of a
previously reported OXA-163-carrying K. pneumoniae isolate [3].
Comparison of the ompK36 gene sequence with the wild-type
sequence revealed an insertion of three nucleotides (50-GAC-30) at
positions 406–408 owing to duplication of the adjacent region at
nucleotide positions 403–405. Sequencing also detected a nine
nucleotide deletion at positions 550–558, a C insertion at
nucleotide position 583, and a four nucleotide insertion (50-
GCGC-30) at position 924. Moreover, 43 nucleotide substitutions
starting from position 210 to 969 were detected. The ompK36
sequence of isolate 181 was assigned accession no. KC977458 in
the GenBank database.
PFGE showed that the two isolates were genetically unrelated
to each other. In addition, MLST attributed to isolates 39 and 181
two different sequence types (STs), ST11 and ST16, respectively.
4. Discussion
The endemic presence of multiresistant enterobacterial strains
carrying the blaNDM-1 gene in India and Pakistan along with
isolation of these strains in other countries, such as the UK,
Australia, USA and France, with epidemiological links with the
Indian subcontinent has been repeatedly reported [1,6,10].
Recently, several reports have also described isolation of NDM-
1-producing enterobacterial strains in Morocco, Oman, United
Arab Emirates and Iran [11–14]. Of interest, the majority of the
cases could not be directly linked to the Indian subcontinent nor
had a history of foreign travel [9–12].
To the best of our knowledge, this is the ﬁrst report of NDM-1-
carrying K. pneumoniae in Egypt. This ﬁnding of an additional case
without an apparent epidemiological link to an endemic area
reinforces the hypothesis of an autochthonous presence of the
blaNDM-1 resistance determinant in the Middle East and North
African area. This is further supported by the identiﬁcation in July
2011 of an NDM-1-producing Acinetobacter baumannii in a Czech
patient repatriated from Egypt [15]. The NDM-1-producing K.
pneumoniae isolate identiﬁed in the current study was shown to
belong to ST11. This pandemic ST has been previously associated
with NDMs in endemic areas [10] as well as with CTX-M-15 and
class A (KPC) and class D oxacillinases [10].ro, Egypt, 2012.
 (mg/mL)a
 CTX CRO FEP LEV CIP GEN MEM IPM ETP COL TIG
6 >256 >256 >256 >32 >32 16 >32 >32 >32 0.038 1
6 >256 >256 >256 >32 >32 0.5 >32 >32 >32 0.025 0.5
ibitory concentration; CAZ, ceftazidime; CTX, cefotaxime; CRO, ceftriaxone; FEP,
M, imipenem; ETP, ertapenem; COL, colistin; TIG, tigecycline.
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been identiﬁed mainly from North African countries, the Middle East,
Turkey and India, but their occurrence in European countries is now
well documented, with some reported hospital outbreaks [10,16].
More recently, OXA-48-like carbapenemases have also been
described in North America [10]. OXA-163, in particular, had
previously been identiﬁed in two K. pneumoniae isolates belonging
to ST20 and ST37, respectively, isolated from two patients staying in
the same cancer hospital in Cairo, Egypt [3]. The present report about
a third OXA-163-carrying K. pneumoniae isolate belonging to ST16
conﬁrms the endemic presence in this healthcare setting of this OXA-
48-like determinant and proves the involvement of an additional
clone. K. pneumoniae ST16 was responsible in the 2000s for
nosocomial outbreaks of CTX-M-15-producing K. pneumoniae in
Europe [17]. This ST has also been reported as carrying KPC-2 in
Brazil, OXA-48 in Spain and NDM-1 in Canada in a patient imported
from India [10,17]. Of interest, isolate 181 had high minimum
inhibitory concentrations for carbapenems and, in this case as well as
in the two previously reported isolates from Egypt, outer membrane
permeability defects were likely contributing to resistance [3].
Dissemination of carbapenemase-producing clones of K. pneu-
moniae and genetic determinants of resistance to carbapenems
appears increasingly wide. Attempts to map their distribution on a
geographic basis appears to be doomed to a continuous update and,
eventually, to failure owing to the inconsistency of surveillance and
the complex worldwide trading network of resistance determinants
and resistant strains. A further element needs to be added in the light
of the recent developments, i.e., international travellers, such as
tourists, foreign workers, immigrants or refugees. The Middle East is
an area of special interest in this respect: indeed, in some countries,
such as Saudi Arabia or United Arab Emirates, approximately one in
three residents are foreign workers, mostly from Egypt, India,
Yemen, Pakistan and the Philippines.
Global antimicrobial resistance surveillance systems supported
by molecular typing, including resource-limited countries where
emergence and spread of new strains and resistance mechanisms
are more likely to occur, are urgently required.
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